STUDY COMPARING THE COMBINED USE OF AVONEX AND COPAXONE

AVONEX 和 COPAXONE 联合使用的比较研究

• 批准号: 7607880
• 负责人: PATRICIA K COYLE
• 金额: $ 0.02万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-23 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607880
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Copaxone; Daily; Dose; Food; Funding; Grant; Institution; Multiple Sclerosis; Muscle; Pharmaceutical Preparations; Purpose; Relapse; Research; Research Personnel; Resources; Skin; Source; Standards of Weights and Measures; United States Food and Drug Administration; United States National Institutes of Health; Week; avonex; copolymer 1

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine whether it is safe,tolerable and effective to use both interferone beta 1a (Avonex) and glatiramer acetate (Copaxone) for the treatment of relapsing multiple sclerosis (RRMS), rather than using only one agent alone. The standard dose for Avonex is 30 mcg administered once a week into the muscle. The standard dose of Copaxone is 20 mg administered daily under the skin. Both, treatments, Avonex and Copaxone are Food and Drug approved drugs. However, the combined use at their standard doses is not FDA approved.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的目的是确定使用干扰素β1A（avonex）和乙酸Glatiramer乙酸盐（Copaxone）是否安全，可忍受和有效，以治疗复发多发性硬化症（RRMS），而不是仅单独使用一种药物。 AVONEX的标准剂量为30 MCG，每周一次施用肌肉一次。 Copaxone的标准剂量每天在皮肤下施用20毫克。治疗，Avonex和Copaxone都是食品和药物认可的药物。但是，标准剂量的合并用途未获得FDA批准。